scispace - formally typeset
A

Angela Casini

Researcher at Technische Universität München

Publications -  292
Citations -  17536

Angela Casini is an academic researcher from Technische Universität München. The author has contributed to research in topics: Carbonic anhydrase & Chemistry. The author has an hindex of 69, co-authored 270 publications receiving 15127 citations. Previous affiliations of Angela Casini include University of Florence & Instituto Superior Técnico.

Papers
More filters
Journal ArticleDOI

Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH.

Eliska Svastova, +10 more
- 19 Nov 2004 - 
TL;DR: It is shown that hypoxia regulates both expression and activity of CA IX in order to enhance the extracellular acidification, which may have important implications for tumor progression.
Journal ArticleDOI

Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs

Alberto Bindoli, +5 more
- 01 Jun 2009 - 
TL;DR: It is proposed that the relevant cytotoxic actions produced by gold compounds are mainly the result of potent inhibition of thioredoxin reductase; the alterations of mitochondrial functions, elicited by profound TrxR inhibition, would eventually lead to cell apoptosis.
Journal ArticleDOI

Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition

Alexander Weber, +6 more
- 29 Jan 2004 - 
TL;DR: An unexpected nanomolar affinity is demonstrated of the COX-2 specific arylsulfonamide-type celecoxib and valdecoxib for isoenzymes of the totally unrelated carbonic anhydrase (CA) family, such as CA I, II, IV, and IX, whereas the rofecoxib methyl sulfone-type has no effect.
Journal ArticleDOI

Gold compounds as anticancer agents: Chemistry, cellular pharmacology, and preclinical studies

Stefania Nobili, +5 more
- 01 May 2010 - 
TL;DR: The state of the art of preclinical studies on anticancer gold compounds, carried out either in vitro or in vivo, are defined and the overall perspectives on the development of gold compounds as effective anticancer drugs with an innovative mechanism of action are critically discussed.
Journal ArticleDOI

A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds

Benoît Bertrand, +1 more
- 19 Feb 2014 - 
TL;DR: In this article, the results obtained for different families of bioactive organometallic gold compounds including cyclometallated gold(III) complexes with C,N-donor ligands, gold(I) and gold (I/III) N-heterocyclic (NHC) carbene complexes, as well as gold( I) alkynyl complexes, with promising anticancer effects.